News
Archives
- 2021
- 2020
- Oct (1)
- Jul (1)
- Apr (1)
- 2019
- Dec (1)
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2018
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2017
- Oct (1)
- Jul (1)
- Apr (1)
- Jan (1)
- 2016
- Oct (1)
- Apr (2)
- Jan (1)
- 2015
- 2014
- 2013
- Oct (1)
- Jul (1)
-
Apr (5)
- First investigator meeting for our new North Asia sites for the first time
- The National Cancer Institute (U.S) has recently labelled Aspirin in Colorectal Cancer as one of the most provocative questions in cancer
- We congratulate Dr Tham and team, and team from Sixth Affiliated Hospital
- Zhejiang and Zhongshan hospitals obtained IRB approval
- PIK3CA subgroup analysis included as a new secondary endpoint
- Jan (2)
- 2012
- Oct (2)
- Apr (1)
- Jan (1)
- 2011
- Oct (1)
- Jul (1)
- Apr (1)
1 Jul 2013
This month the Womens Health Study has turned positive after 18 years of follow up
This month the Womens Health Study has turned positive after 18 years of follow up. This prospective randomized study showed that aspirin is effective in the primary prevention of colon cancer, in healthy middle aged women. Since the NNT to prevent one new colon cancer is very high and because there was no improvement in all-cause mortality, there is still general caution against the widespread recommendation for aspirin prophylaxis in normal risk individuals. Nevertheless, the confirmation of biological efficacy for aspirin is generating considerable excitement and makes our adjuvant ASCOLT study more relevant than ever.